SCHEMBL3003284

SCHEMBL3003284

O=[N+]([O-])c1cccc(S(=O)(=O)C2CCN(c3nc(-c4ccc(Cl)cc4Cl)cs3)CC2)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AR P10275 1/20 0.50
SMN1; SMN2 Q16637 4/20 0.44
MAPT P10636 3/20 0.44
KDM1A O60341 4/20 0.44
RAB9A P51151 2/20 0.42
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
NPC1 O15118 1/20 0.42
POLB P06746 1/20 0.42
NPSR1 Q6W5P4 2/20 0.41
FLT1 P17948 1/20 0.39
FLT4 P35916 1/20 0.39
KDR P35968 1/20 0.39
LMNA P02545 3/20 0.39
HTT P42858 2/20 0.38
MAOA P21397 1/20 0.38
ALDH1A1 P00352 1/20 0.38
GAA P10253 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
PIK3CD O00329 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3008958 0.91 AR (0.53) ARSMN1; SMN2MAPTKDM1ARAB9A
SCHEMBL3003356 0.89 AR (0.57) ARSMN1; SMN2MAPTKDM1ARAB9A
SCHEMBL3020379 0.89 SMN1; SMN2 (0.58) SMN1; SMN2MAPTKDM1ARAB9AMEN1
SCHEMBL3004475 0.88 SMN1; SMN2 (0.49) SMN1; SMN2MAPTKDM1ARAB9AMEN1
SCHEMBL3008900 0.87 AR (0.53) ARSMN1; SMN2MAPTKDM1ARAB9A
SCHEMBL3017157 0.86 AR (0.60) ARSMN1; SMN2MAPTRAB9ANPC1
SCHEMBL3015599 0.86 AR (0.53) ARSMN1; SMN2MAPTRAB9AMEN1
SCHEMBL3006979 0.86 AR (0.53) ARSMN1; SMN2MAPTKDM1ARAB9A
SCHEMBL3016907 0.85 AR (0.57) ARSMN1; SMN2MAPTRAB9ANPC1
SCHEMBL2998624 0.85 AR (0.49) ARSMN1; SMN2MAPTKDM1ARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA AR 3801/4885SMN1; SMN2 1/4885MAPT 18/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.